Longevity.International Presents: Biomarkers Of Human Longevity

(June 30, 2021)

Join us on June 30th, 2021, 5pm - 8pm BST for “Longevity.International presents: Biomarkers Of Human Longevity”, a virtual 1-day conference featuring presentations from a variety of companies, key players and thought-leaders active within the Biomarkers of Human Aging and Longevity Industry.
The event will explore the present state of the industry, as well as key strategic challenges and opportunities for translating the potentials of Biomarkers of Human Longevity from theory into practice.

During the event, Franco Cortese (Director, Aging Analytics Agency) will be joined by a number of executives from key companies developing Biomarkers of Human Longevity, including Deep Longevity, Biocanic, Life Length, GlycanAge and Jinfiniti Precision Medicine, who will present overviews of their recent innovations in the field, followed by a talk on the role of biomarkers in policy, regulatory development and the clinical validation of Longevity-focused therapeutics by the Kitalys Institute, and concluding with a panel discussion.

The event coincides with the public launch of “The Rising Wave of Human Biomarkers of Longevity: Landscape Overview 2021”, a new special analytical case study and interactive IT-Platform produced by Aging Analytics Agency for Longevity.Internatonal, which uses comprehensive analytical frameworks to rank and benchmark existing panels of biomarkers of aging, health and Longevity according to their ratios of accuracy vs. actionability, identifying the panels of biomarkers that can have the greatest impact on increasing both individual and national Healthy Longevity in the next few years, for use by a wide variety of strategic decision makers including companies, investors, governments and insurance companies.

All Speakers Banner V2.png



Fedor Galkin

Director Of Scientific BD, Deep Longevity

Fedor Galkin was working with Insilico Medicine since 2018 and in 2020 transferred to its spin-off Deep Longevity — a Hong Kong startup focused on digital solutions for longevity medicine. He is conducting research on biomarkers of aging and the ways to reverse this process.

He is also involved in adapting the aging clock technology for clinical, consumer, and corporate use cases. The deep learning models developed by Deep Longevity are available for academic use at aging.ai and for consumers at young.ai


Prof Sc.D Gordan Lauc

CSO & Co-Founder GlycanAge

Gordan Lauc is the Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Scientific Excellence in Personalised Healthcare, honorary professor at the University of Edinburgh and the King’s College London and member of the Johns Hopkins Society of Scholars. 


Professor Lauc co-authored over 200 research articles that are cited over 5,000 times. He was PI and co-PI in four NIH, two FP6, seven FP7, six H2020, and three ESI Funds projects and coordinated five of them. In 2007 he founded Genos, a biotech

company that is currently the global leader in high-throughput glycomics.


Jeremy Malecha

CEO and co-founder of Biocanic

Jeremy Malecha is CEO and co-founder of Biocanic with over 20 years of medical and software related experience. Prior to Biocanic, he was the Vice President of M&A Strategy in ResMed’s Software as a Service Business. 

Across his 10+ year career at ResMed he also held senior leadership roles overseeing global product management across the product portfolio and was the lead person behind the conceptualization and launch of the ResMed digital health ecosystem. 

Jeremy holds a Bachelor of Engineering in Biomedical Engineering from Northwestern University in addition to 6 patents in non-linear signal processing for medical applications.



Dr. Nuria De Pedro

Chief Scientific Officer, Life Length

Dr. Nuria de Pedro is the Chief Scientific Officer and Chief Laboratory Officer of Life Length.  

She obtained her PhD in biochemistry and molecular biology from Autonoma University of Madrid. She possesses over 15 years’ experience in pharma companies. Published author of 30+ manuscripts in international scientist journals, 1 book chapter and 6 patents (Oncology and Neurodegeneration diseases). She joined Life Length in 2016, since then she has led the automation process, clinical trials, process and products development under quality accreditations and certifications.



Dr. Jin-Xiong She

Founder and CEO, Jinfiniti Precision Medicine

Dr. Jin-Xiong She is the Founder and CEO of Jinfiniti Precision Medicine, a company developing approaches to measure aging biomarkers to prevent age-related diseases and maximize health and lifespan via data-driven changes of lifestyle and nutraceuticals. Jinfiniti is launching a biomarkers test panel that measures genomic instability, epigenetic alteration, inflammation, cellular senescence, oxidative stress, tissue damage, and key micronutrients. 


Dr. Alexander Fleming 

Executive Chairman, The Kitalys Institute

Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum. He is also President and Chief Executive Officer of Tolerion, a biotechnology company developing “disease-modifying” treatments for type 1 diabetes and other autoimmune diseases.

Dr. Fleming coined the term “Metabesity,” which refers to the constellation of cancer, heart and neurologic diseases, diabetes, and the aging process itself, all of which share common metabolic root causes and potential preventive therapies. He organized the first Congress on Metabesity in London in October 2017, followed by the second Congress in Washington, D.C., in 2019, and now the third Congress in 2020.


Ian Inkster

Project Coordinator, Longevity.International

Ian Inkster has worked across multiple biotech companies since 2009 with an emphasis on giving definition to the rejuvenation biotechnology industry.

Ian is working as Chief-Of-Policy at Biogerontology Research Foundation. He had a hand in the SENS Research Foundation since its inception, and his previous role was as a public relations officer for Deep Knowledge Ventures.


Franco Cortese

Director, Aging Analytics Agency

Franco Cortese is Director of Aging Analytics Agency, and has been a member of the company’s executive management team since its inception.

He is one of the co-creators of the Longevity Industry Framework behind many of the company’s Longevity Industry analytics, benchmarking and forecasting.

He is also one of five co-authors behind the proposal that led to the World Health Organization's addition of a new extension code for aging-related diseases (XT9T) during ICD-11, and the author of over a dozen scientific papers in peer-reviewed journals.


Dmitry Kaminskiy

General Partner at Deep Knowledge Group

Dmitry Kaminskiy is an innovative entrepreneur and investor active in the fields of Longevity, Precision Medicine, and Artificial Intelligence. He is co-founder and managing partner at Deep Knowledge Ventures, a leading investment fund focused on DeepTech, renowned for its use of sophisticated analytical systems for investment target identification and due-diligence. 


He is a frequent speaker on AI and Longevity, including events organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, Financial Times “Global Pharmaceutical and Biotechnology Conference”, the "Precision Medicine World Conference" in Silicon Valley as well as others at Oxford and Cambridge Universities.


5:00 - 5:05: Franco Cortese (Director, Aging Analytics Agency)
Opening Remarks

5:05 - 5:15: Ian Inkster (Project Coordinator, Longevity.International)
Longevity.International - A Decentralized Industry Knowledge and Collaboration Platform to Support Industry Harmonization

5:15 - 5:30: Franco Cortese (Director, Aging Analytics Agency)
Biomarkers Of Human Longevity as the Critical Catalyst for Longevity Industrialisation, Governance and Practical Applications

5:30 - 5:45: Fedor Galkin, Director Of Scientific BD, Deep Longevity

Building longevity medicine infrastructure. Why aging clocks matter

5:45 - 6:00: Prof Sc.D Gordan Lauc - CSO & Co-Founder, GlycanAge   

Glycans are biomarkers and functional effects of aging: can we make glycans young again and prevent inflammaging?

6:00 - 6:15: Dr. Nuria De Pedro, Chief Scientific Officer,  Life Length

Telomeres and Longevity

6:15 - 6:30: Jeremy Malecha, CEO at Biocanic

Biocanic: Physiological Lab Data Insights and Learnings from the Real World

6:30 - 6:45: Dr. Jin-Xiong She, Founder and CEO, Jinfiniti Precision Medicine 

Personalized NAD Optimization via at home testing

6:45 - 7:00: Dr. Alexander Fleming (Executive Chairman, The Kitalys Institute)

The Role Of Biomarkers For Aging In Regulatory Development

7:00 - 7:15: Dmitry Kaminskiy (General Partner, Deep Knowledge Group)


7:15 - 7:55: Panel Discussion

7:55 - 8:00: Franco Cortese (Director, Aging Analytics Agency)

Closing Remarks